Mithra

Mithra Pharmaceuticals S.A. develops, manufactures, and markets complex therapeutics primarily for treating women's fertility, contraception, and menopause needs in Belgium, the Netherlands, Luxembourg, and internationally. Its two lead development candidates include Estelle, which is in a Phase III clinical trial, a fifth generation oral contraceptive in Europe and North America under the E4 Freedom name; and Donesta, which is in a Phase II clinical trial that is used for a new generation of hormone therapy with the oral administration of Estetrol (E4) for vasomotor menopausal symptoms relief. The company's research and development pipeline consists of three therapeutics comprising Myring, a contraceptive vaginal ring releasing a combination of hormones; Zoreline, a biodegradable subcutaneous implant for use in prostate and breast cancers, and benign gynecological indications; and Tibelia, a solution for treating menopause and osteoporosis. It provides products in polymeric forms, sterile injectable products, and hormonal tablets. Mithra Pharmaceuticals S.A. was founded in 1999 and is headquartered in Liège, Belgium.